What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
The scientist’s investigation covers issues in Internal medicine, Leukemia, Chronic lymphocytic leukemia, Gastroenterology and Immunology.
His Internal medicine research incorporates elements of Surgery and Oncology.
His studies in Leukemia integrate themes in fields like Survival rate, Myeloid leukemia, Pharmacology and Lymphoma.
Michael J. Keating has included themes like Cancer research, microRNA and Minimal residual disease in his Chronic lymphocytic leukemia study.
He has researched Gastroenterology in several fields, including Refractory, Chronic myelogenous leukemia, Toxicity, Acute lymphocytic leukemia and Acute leukemia.
Michael J. Keating interconnects Cytotoxic T cell and Glutathione in the investigation of issues within Immunology.
His most cited work include:
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (4145 citations)
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
- Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy (1097 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Chronic lymphocytic leukemia, Immunology, Leukemia and Gastroenterology.
His Internal medicine study combines topics from a wide range of disciplines, such as Surgery and Oncology.
His Chronic lymphocytic leukemia research is multidisciplinary, incorporating perspectives in Cancer, Cancer research and Pathology.
His Immunology research focuses on Myeloid leukemia in particular.
His Leukemia study integrates concerns from other disciplines, such as Lymphoma, Bone marrow and Pharmacology.
Michael J. Keating combines subjects such as Phases of clinical research, Cytarabine, Regimen, Neutropenia and Acute lymphocytic leukemia with his study of Gastroenterology.
He most often published in these fields:
- Internal medicine (40.14%)
- Chronic lymphocytic leukemia (37.04%)
- Immunology (24.12%)
What were the highlights of his more recent work (between 2014-2021)?
- Chronic lymphocytic leukemia (37.04%)
- Internal medicine (40.14%)
- Ibrutinib (6.43%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Cancer research and Oncology.
A component of his Chronic lymphocytic leukemia study involves Leukemia and Immunology.
Michael J. Keating focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Gastroenterology and, in certain cases, Phases of clinical research.
His research in Ibrutinib intersects with topics in Discontinuation, Obinutuzumab, Venetoclax, Pharmacology and Bruton's tyrosine kinase.
His Cancer research research integrates issues from Apoptosis, STAT3, breakpoint cluster region and Bone marrow.
His research investigates the connection between Oncology and topics such as Clinical trial that intersect with problems in Adverse effect.
Between 2014 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (305 citations)
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia (296 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Michael J. Keating focuses on Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Leukemia and Cancer research.
His Chronic lymphocytic leukemia research is within the category of Immunology.
His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology.
His research integrates issues of Venetoclax, Tyrosine kinase, Bruton's tyrosine kinase and Pharmacology in his study of Ibrutinib.
The study incorporates disciplines such as Targeted therapy, Malignancy, Lipoprotein lipase and Intensive care medicine in addition to Leukemia.
His Cancer research research focuses on STAT3 and how it connects with Chromatin immunoprecipitation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
